{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:55:43Z","timestamp":1785041743830,"version":"3.55.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Autologous second-generation CD7-directed chimeric antigen receptor T cells, expressing an anti-CD7 protein expression blocker to prevent self-killing fratricide, were infused in 3 pediatric\/young adult patients with relapsed\/refractory CD7+ acute myeloid leukemia, resulting in measurable residual disease negativity. The safety profile was favorable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032299","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:05:08Z","timestamp":1772557508000},"page":"2981-2985","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-4092","authenticated-orcid":false,"given":"Marco","family":"Becilli","sequence":"first","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-4046","authenticated-orcid":false,"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"},{"name":"2Department of Medicine and Surgery, Saint Camillus International University of Health Sciences, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"},{"name":"3Department of Health Sciences, Magna Graecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-3465","authenticated-orcid":false,"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Pagliara","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9028-7767","authenticated-orcid":false,"given":"Valentina","family":"Bertaina","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-0927","authenticated-orcid":false,"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosignoli","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cefalo","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Boccieri","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-9261","authenticated-orcid":false,"given":"Stefano","family":"Di Cecca","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iaffaldano","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqin","family":"Lee","sequence":"additional","affiliation":[{"name":"4Discovery Sciences, MediSix Therapeutics, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-737X","authenticated-orcid":false,"given":"Biagio","family":"De Angelis","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"5Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-9705","authenticated-orcid":false,"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"},{"name":"6Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"8National University Cancer Institute, National University Hospital, National University Health System, Singapore, Singapore"},{"name":"9Cancer Science Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"},{"name":"10Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026061111215459700_bib1","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41375-022-01619-9","article-title":"Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies","volume":"36","author":"Zarnegar-Lumley","year":"2022","journal-title":"Leukemia"},{"issue":"6165","key":"2026061111215459700_bib2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"5","key":"2026061111215459700_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026061111215459700_bib4","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026061111215459700_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"2026061111215459700_bib6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"2026061111215459700_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2026061111215459700_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol Ther"},{"issue":"9","key":"2026061111215459700_bib9","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","article-title":"CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them","volume":"7","author":"Vanhooren","year":"2023","journal-title":"Hemasphere"},{"issue":"23","key":"2026061111215459700_bib10","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1182\/bloodadvances.2025017011","article-title":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv"},{"issue":"25","key":"2026061111215459700_bib11","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"2026061111215459700_bib12","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2026061111215459700_bib13","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bjh.19446","article-title":"Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression","volume":"204","author":"Jen","year":"2024","journal-title":"Br J Haematol"},{"issue":"9","key":"2026061111215459700_bib14","doi-asserted-by":"crossref","first-page":"e98561","DOI":"10.1172\/jci.insight.98561","article-title":"Universal monitoring of minimal residual disease in acute myeloid leukemia","volume":"3","author":"Coustan-Smith","year":"2018","journal-title":"JCI Insight"},{"issue":"10","key":"2026061111215459700_bib15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcyt.2025.05.013","article-title":"Hospital exemption in Italy: technical-scientific and regulatory aspects in comparison with Europe","volume":"27","author":"Ambrosone","year":"2025","journal-title":"Cytotherapy"},{"key":"2026061111215459700_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel","author":"Zwaan","year":"2026;147(14):1532-1561","journal-title":"Blood"},{"issue":"12","key":"2026061111215459700_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026061111215459700_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026061111215459700_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026061111215459700_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026061111215459700_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"2026061111215459700_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026061111215459700_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"16","key":"2026061111215459700_bib24","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2981\/2525718\/blood_bld-2025-032299-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/24\/2981\/2525718\/blood_bld-2025-032299-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:22:00Z","timestamp":1781191320000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/24\/2981\/566909\/Anti-CD7-fratricide-resistant-chimeric-antigen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032299","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,11]]},"published":{"date-parts":[[2026,6,11]]}}}